# Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

> **NCT00630201** · PHASE3 · COMPLETED · sponsor: **Titan Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Opioid Dependence

## Interventions

- **DRUG:** Probuphine (buprenorphine implant)

## Key facts

- **NCT ID:** NCT00630201
- **Lead sponsor:** Titan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630201, "Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00630201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*